A Study of SRSD107 in Participants With Chronic Coronary and/or Peripheral Arterial Disease

NCT07318155 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

104

Enrollment

INDUSTRY

Sponsor class

Conditions

Coronary Artery Disease (CAD)
Peripheral Arterial Disease

Interventions

DRUG: SRSD107
DRUG: 0.9 % sodium chloride

Sponsor

Sirius Therapeutics Co., Ltd.